High-sensitivity cardiac troponin T (cTnT) assays detect small clinically important myocardial infarctions (MI) but also yield higher rates of false-positive results owing to increased concentrations sometimes present in patients without MI. Better understanding is needed of factors influencing the 99th percentile of cTnT concentrations across populations and the frequency of changes in cTnT concentrations Ͼ20% often used in combination with increased cTnT concentrations for diagnosis of MI.
High-sensitivity troponin assays allow reliable measurements of troponin concentrations below the 99th percentile (1 ) and help clinicians find small myocardial infarctions (MIs) 6 with improved diagnostic sensitivity. These assays shorten the time to diagnosis by 3 h compared to the use of conventional troponin assays with blood sampling at admission and after 3 and 6 h (2, 3 ). On the other hand, high-sensitivity troponin assays also increase the number of patients presenting with increases in troponin from other causes than MI (4, 5 ) . Such increases are particularly common in elderly patients (6 ) , and lead to reductions in the diagnostic specificity of troponin results. However, increases in troponin that can be found only with highsensitivity assays have strong prognostic implications even in the absence of MI (7, 8 ) . In addition, a recent report indicated that if patients with suspected coronary syndromes and troponin concentrations above the 99th percentile as measured with a sensitive troponin assay are treated as having suspected MIs, mortality rates and recurrent MIs decrease by 50% (9 ) . This report underscores the importance of finding and treating the smallest MIs and of implementing highsensitivity troponin assays in clinical routines. To increase the diagnostic accuracy it is also critical to assess the changes in troponin concentrations over time. Although the magnitude of the change that is required for a diagnosis of MI remains unclear, relative changes that range from 20% to 117% (3, 4, 10 -12 ) or absolute 2-h changes of 7 ng/L (13 ) have been suggested. Against this background, it is important to know the frequency of troponin increases and the range of changes in troponin concentrations observed in patients who commonly undergo clinical assessment with troponin measurements.
We have therefore determined nonparametrically the cardiac troponin T (cTnT) percentiles (14 ) in 3 populations of relevance to clinical situations in which cTnT is evaluated. We determined the age-dependent 99th cTnT percentiles in a random sample of individuals and in emergency room (ER) patients without apparent conditions associated with increased cTnT concentrations. We also determined the changes in cTnT over time in coronary care unit patients without MI and the first cTnT percentile in patients with developing non-ST-elevation MI (NSTEMI), according to the time after symptom presentation and the time after admission at the ER.
Study Participants and Methods

STUDY DESIGN AND POPULATIONS
TnT percentiles were calculated in 3 populations (Table 1). The study was approved by the ethics committee at the University of Gothenburg, and the study protocol followed the ethics guidelines of the 1975 Declaration of Helsinki. First, a random population sample was recruited from the third population screening in 1995 of the WHO study MONItoring of trends and determinants for CArdiovascular disease (MONICA), Gothenburg, Sweden (15 ) . The original cohort comprised 1200 men and 1200 women, 25-64 years old, from the city census, who were included in a worldwide project in 38 countries. The participation rate varied from 52% (young men) to 82% (older women). In 1995, every fourth participant in the age groups 25-34, 35-44, 45-54, and 55-64 years in men and 25-34 and 35-44 years in women and all women in the age groups 45-54 and 55-64 years were randomly selected for extensive hormone blood screening (662 individuals in total). In 2008, 539 individuals were successfully traced and invited to a reevaluation. Blood samples and records from the reexamination in 2008 were available for 413 individuals (i.e., a 77% participation rate). Medical records, diagnosis records, N-terminal pro-brain natriuretic peptide, estimated glomerular filtration rate, and 39 other laboratory variables were evaluated for all participants. Individuals were excluded from the percentile calculations if they had medical conditions known to increase cTnT, such as kidney failure or heart failure. On the basis of this evaluation, 10 of the 413 individuals were excluded. The percentiles in Table 2 and Supplementary  Table 1 (in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/ content/vol58/issue3) are calculated on the basis of the remaining 403 individuals.
The second study population included patients from the Sahlgrenska University Hospital ER, who were asked to participate in the study from March 2010 to September 2010 if they were triaged to levels "yellow" (level 3) or "orange" (level 4) according to the 5 levels of the Medical Emergency Triage and Treatment System (METTS)-A triage algorithm (16 ) . The METTS-A triage tool combines vital signs and 43 categorized symptoms, such as chest pain, dyspnea, and vertigo, to prioritize patients to different levels of attendance. Priority level "orange" is classified as potentially life threatening, requiring medical attention within 20 min, and priority level "yellow" is classified as not life threatening but requiring medical attention within 120 min. Patients seeking care for symptoms deemed to require evaluation of heart markers according to the METTS-A algorithm were excluded. Therefore, all patients with symptoms indicative of acute coronary syndrome or patients prioritized to level "blue" (level 1), "green" (level 2), or "red" (level 5) on the METTS-A triage scale were excluded. During this period, 693 patients agreed to participate. A serum sample was collected at triage and cTnT was analyzed within 2 hours. One patient was found to have an MI and was therefore excluded. Two patients with cTnT Ͼ13 ng/L died before evaluation, and 3 patients who could not be reached for medical examination were excluded. The remaining 687 patients were used to calculate the cTnT values presented in Table 2 in the ER (all) section. We wanted to determine cTnT percentiles in ER patients who lacked any sign of acute coronary syndrome or conditions associated with increases in cTnT concentrations that the ER doctor could identify on the basis of a medical examination, medical records, electrocardiogram, and blood tests, such as heart failure, atrial fibrillation, infection, and renal failure. Therefore, patients with a cTnT Ͼ13 ng/L [i.e., above the previously determined 99th cTnT percentile (17 )] were referred for a medical examination that included electrocardiogram, blood work-up including cTnT, estimated glomerular filtration rate, N-terminal pro-brain natriuretic peptide, C-reactive protein, aspartate aminotransferase, alanine transaminase, and an evaluation of lifestyle factors and medical records within 1-2 weeks of the ER visit. In addition, all medical records of patients with cTnT Ͼ9 ng/L were carefully examined to rule out conditions associated with increased cTnT concentrations. Patients were excluded from the calculations if they were found to have conditions associated with increased cTnT concentrations (18 ) . Patients were also excluded from the calculations if the change in cTnT concentrations between the sample taken at the ER and the blood sample at the 1-2-week follow-up was Ͼ39% (i.e., half of the reference change value determined in a local healthy population). Of a total of 687 patients, 36 (5%) had cTnT Ͼ9 ng/L and conditions associated with increased cTnT concentrations and were therefore excluded from the calculations. The cTnT values shown in Table 2 in the ER section, Fig. 1 , and online Supplementary Table 2 were calculated on the basis of the remaining 651 patients. The third population was drawn from a coronary care unit patient population registered in the Swedeheart (Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies) registry (19, 20 ) . The more than 100 variables in the Swedeheart registry comply with the International Cardiology Audit and Registration Data Standards (21 ) . A total of 5044 patients recorded in the Swedeheart registry in the Gothenburg area were available during the 11 months (December 2009 to November 2010) following introduction of the high-sensitivity cTnT assay (December 2009). Only patients admitted after the introduction of the highsensitivity cTnT assay were included in the study.
Changes in the cTnT concentration (Table 3) were determined in patients admitted to the coronary care unit with a final diagnosis of heart failure, atrial fibrillation, stable angina pectoris, and noncardiac chest pain. Patients with particular diagnosis combinations within each diagnosis group were excluded, such as heart failure or atrial fibrillation in noncardiac chest pain patients. All patients who died or had a diagnosis of MI within 6 months according to the Swedeheart registry were excluded from the cTnT change percentile calculations. Patients who underwent coronary angiography or cardiopulmonary resuscitation while in the coronary care unit were excluded. In addition, within each diagnosis group, medical records were carefully checked when the cTnT concentration was close to the diagnosis-dependent 97.5th cTnT percentile or if the change in the cTnT concentration was Ͼ50%. Patients were excluded if any conditions asso- ciated with increases in cTnT concentrations other than the Swedeheart diagnosis were identified. Only cTnT measurements during the stay in the coronary care unit were included in the calculations.
NSTEMI was diagnosed in patients by a cardiologist who used the current guidelines (22 ) and reviewed data from a physical examination, imaging, electrocardiogram and laboratory tests collected during the stay in the coronary care unit . During the study, the cTnT concentration threshold of 40 ng/L used to trigger hospital admission and serial blood sampling for diagnostic evaluation of acute coronary syndrome was based on the imprecision (CV Ͻ10%) of the previous fourthgeneration cTnT assay (23 ) . In patients with NSTEMI, the time of symptom onset and of the final diagnosis recorded in the Swedeheart registry were carefully checked against the medical records and ambulance records if the cTnT concentrations or changes in the cTnT concentrations were low during the first 24 h. Patients without clear diagnoses were excluded. The time of symptom onset was adjusted accordingly for patients who developed MI while in the coronary care unit. In approximately 10% of the cases, the time of symptom onset was unclear and was thus recorded as the ambulance alarm time or as the arrival time at the ER. The admission frequency and age distribution in patients presenting with chest pain, shown in Table 1 , were retrieved from a 6-month registry of all ER patients at the Sahlgrenska University Hospital ER in 2005. A similar but less thorough recording of patients admitted to the same ER in 2010 showed values similar to those shown in Table 1 .
LABORATORY METHODS
cTnT was measured with the Elecsys hscTnT immunoassay on a fully automated Modular® Analytics E170 with a limit of the blank as determined by the manufacturer of 3 ng/L. The within-run, between-run, and long-term CVs are provided in online Supplementary  Table 3 and were in conformity with the previously reported precision (17 ) . The reference change value for cTnT was 79%, as determined from measurements in a local population of 71 thrombocyte donors with a sampling interval of 2 weeks. The estimated glomerular filtration rates were calculated from serum cystatin C concentrations, as measured with a particle-enhanced turbidimetric immunoassay (DACO-Cys-C) on a Cobas 6000 and using the formula: estimated glomerular filtration rate ϭ [79/cystatin C (mg/L)] Ϫ 13.8 mL ⅐ min Ϫ1 ⅐ (1.73 kvm) Ϫ1 . All other laboratory anal- a Number of cTnT measurements included in calculations. b NA, not applicable, because the absolute change in cTnT concentration differed among diagnosis groups (heart failure vs atrial fibrillation, stable angina pectoris, and noncardiac chest pain, all P Ͻ0.02, and atrial fibrillation vs stable angina pectoris, P ϭ 0.017, for difference in medians).
yses were part of the routine analyses performed at the Sahlgrenska University Hospital Laboratory by using the Modular system (Roche Diagnostics).
STATISTICAL ANALYSIS
Nonparametric reference values and 95% CIs were calculated by using RefVal4.0 without outlier deletion (24 ) . The CIs were calculated with the use of 10 000 bootstrap iterations. For the data in Table 2 and Figs. 1  and 2 , the CIs of the percentiles were calculated on the basis of a binomial distribution by using Stata 11.0. A moving window was used for the analysis of agedependent and time-dependent percentiles. Testing of the difference in cTnT distributions between males and females was performed by using the KolmogorovSmirnov test and Stata 11.0. The 95% CIs for percentiles in Table 3 were estimated by using a binomial method and making no assumptions about the underlying distribution of the variable. Differences in medians were tested by using the Wilcoxon rank-sum test.
Results
TnT PERCENTILES IN A RANDOM POPULATION SAMPLE
The cTnT percentiles in a random population sample of 403 individuals with a median age of 65 years are shown in Table 2 . A cTnT concentration above the limit of the blank (3 ng/L) was seen in 33% of all study participants and was age dependent (Table 2 ). We calculated age-dependent nonparametric percentiles for cTnT using a moving window of overlapping samples from 110 -293 individuals in age groups that ranged from 39 -58 to 59 -78 years (see online Supplementary  Fig. 1 ). The age-dependent 99th percentile was 12.7 ng/L in the 2 youngest groups (39 -59 years) but rose to a stable concentration around 25 ng/L when the calculations included individuals older than 60 years (see online Supplementary Fig. 1 and online Supplementary Table 1 ). Among individuals Ͼ65 years old, men had significantly higher age-adjusted cTnT concentrations than women (P ϭ 0.0003). Thus, the 99th cTnT percentile in this random population sample of individuals with no apparent conditions associated with increases in cTnT appeared to be age dependent, with an apparent breakpoint around 60 years of age.
TnT PERCENTILES IN ER PATIENTS
A cTnT concentration above the limit of the blank (3 ng/L) was detected in 47% and a concentration above the 99th percentile was detected among healthy individuals (14 ng/L) (17 ) in 9% of ER patients without acute coronary syndromes or other overt conditions associated with increases in cTnT (ER data, Table 2 ). In patients younger than 65 years, the cTnT percentiles showed little age dependence, and the 99th cTnT percentile was stable around 10 -12 ng/L, with narrow CIs (Fig. 1B, Table 2 ). When patients older than 65 years were included, the percentiles became highly age dependent ( Fig. 1B ; also see online Supplementary Table  2 ). The percentage of patients with cTnT concentrations above different cutoff points was dramatically different for patients above or below 65 years of age (Fig. 1C) . Male ER patients had higher cTnT percentiles and more frequently had cTnT concentrations above different cutoff points (Table 2 ). In addition, age-adjusted cTnT concentrations were significantly higher among male patients, both among those below (P ϭ 0.002) and those above (P ϭ 0.0001) 65 years of age. Thus, the cTnT percentiles in ER patients with no apparent conditions associated with increases in cTnT appeared to be highly age dependent, with a sharp breakpoint at 65 years.
CHANGE IN THE cTnT CONCENTRATION IN CORONARY CARE UNIT PATIENTS WITHOUT MI
For all the conditions examined, the 50th percentile for relative changes in the cTnT concentration was 9%-12%, and the 97.5th percentile for relative changes was 51%-67% (Table 3 ). In contrast, absolute changes in cTnT concentrations were diagnosis dependent, likely reflecting different underlying cTnT concentrations in each patient group. Because the underlying condition had no clear impact on the relative change in cTnT, data from all patients were combined to examine relative changes in the cTnT concentration according to the time between sampling or according to initial cTnT concentrations (Table 3 ). There was a non-statistically significant increase in the relative change in cTnT concentration as the time between blood samples increased from 0 -3 to 6 -9 h. There was no clear correlation between the stable cTnT concentration and the relative change in the cTnT. As expected, the absolute change was higher among patients with higher cTnT concentrations. We conclude that the upper reference limit for the relative change in the cTnT concentration is 48%-92%, irrespective of underlying stable heart conditions, sampling time, and stable cTnT concentrations, whereas the absolute change is dependent on the initial cTnT concentration.
TnT PERCENTILES IN PATIENTS WITH NSTEMI
The relationship between the elapsed time after symptom presentation (symptom time) or the time after arrival at the ER (ER time) and the cTnT percentiles was determined in 452 NSTEMI patients in the first 24 h (Table 4 and Fig. 2 ; also see online Supplementary Fig.  2 ). The median time between symptom onset and arrival at the ER was 2.7 h. The cTnT percentiles increased during the first 14 h after symptom onset and then declined (Fig. 2, B and C) . The cTnT percentiles increased during the first 6 h after arrival at the ER and then plateaued (see online Supplementary Fig. 2 , B and C). Approximately 14% of the NSTEMI patients arrived at the ER with increased cTnT concentrations that changed Ͻ20%, preventing calculation of meaningful percentiles of changes in cTnT concentrations. No significant difference in cTnT concentrations was found between men and women. A conservative estimate using the lower 95% CI of the 1st cTnT percentile (Table 4) indicated that in 99% of the NSTEMI patients cTnT reached concentrations above 12 ng/L after a median symptom time of 8.5 h or a median ER time of 6 h.
Discussion
The current study resulted in 3 main findings that will help in the evaluation of cTnT measurements in ER patients. The first finding was that cTnT percentiles in ER patients without obvious conditions associated with increases in cTnT, such as heart failure, kidney failure, and atrial fibrillation, were highly age dependent above a breakpoint around 65 years, similar to previous findings with the use of troponin I (8, 25 ) and cTnT (17 ) assays. However, this age dependence was evident only in ER patients older than 65 years. In ER patients younger than 65 years, the 99th cTnT percentile was 12 ng/L with narrow CIs (Fig. 1B, Table 2 ). Although the CIs overlapped, and the difference did not reach statistical significance, this value was lower than the previously determined 99th cTnT percentile of 14 ng/L (17 ) in a cohort of 533 healthy individuals. This finding was unexpected, because our ER population comprised relatively unwell patients triaged to level 3 or 4 on the 5-grade triage scale. However, the previous study also included individuals Ͼ65 years old who may have influenced the percentiles. The low frequency of increases in cTnT and the fact that 50% of all chest pain patients were Ͻ65 years old at the local ER (Table 1) indicate that there would be only 61 extra admissions for serial sampling/year in this age group if the cTnT decision threshold were to be lowered from 40 ng/L to 12 ng/L at the local ER, where 4800 chest pain patients are seen annually. In contrast, the cTnT concentrations in ER patients above 65 years of age were highly age dependent, resulting in an increased need for serial cTnT sampling in this age group if a lower cTnT decision threshold were to be implemented (Fig. 1C) . However, 66% of ER patients older than 65 years had cTnT concentrations below 12 ng/L ( Table  2 ), indicating that age-stratified cTnT decision thresholds (6 ) will limit our ability to provide the elderly with the possible survival benefit associated with finding and treating MIs that can be found only with sensitive troponin assays (9 ) . The percentiles presented here allow estimation of the projected impact of different cTnT decision thresholds on the admission frequency for serial sampling and hospital costs. Our analyses of the 1st cTnT percentile in patients with NSTEMI may be used to estimate the observation time required to exclude NSTEMI with a given certainty. cTnT increases within a few hours after the onset of ischemia, reaching a maximum at 12-15 h (26 ) . Meaningful cTnT percentiles must therefore be related to ischemia duration. Although the patient-reported time of symptom onset is an uncertain surrogate marker for the onset of ischemia, this time point is used routinely to assess the clinical importance of low cTnT concentrations. The second finding in this study was that a conservative estimate of the 1st percentile of cTnT in NSTEMI patients remained below 12 ng/L until 8.5 h after onset of symptoms, and 6 h after arrival at the ER. These findings indicate that patients with suspected acute coronary syndrome should be monitored with additional cTnT measurements during these time periods before NSTEMI can be excluded. If higher cTnT decision thresholds are used, longer observation times may be needed (Table 4) (A), cTnT percentiles in NSTEMI patients according to the time since symptom onset (symptom time). The median symptom time-dependent 1st (B) and 2.5th (C) nonparametric cTnT percentiles from overlapping sets of 102-208 cTnT measurements with symptom time ranges from 3-6 h to 18 -24 h. The actual percentiles and symptom times are presented in Table 4 . Thin lines indicate the 95% CI; n indicates number of cTnT measurements.
The optimal discriminating value for MI diagnosis in terms of change in the cTnT concentration has been debated (3, 4, 10 -13 ) . The third finding in our study was that the 97.5th percentile for change in the cTnT concentration; i.e., the upper reference limit, was 51%-67% in actual coronary care unit patients without MI. Although most patients had a cTnT change of Ͻ10%, the MI diagnosis must rely on changes that are greater than what is commonly observed in patients without ongoing myocardial damage. Our data indicate that 2.5% of patients with stable cTnT elevations would incorrectly receive an MI diagnosis if a 60% change in the cTnT concentrations were used for the MI diagnosis. If the MI diagnosis relied on a lower value of cTnT change, even more patients with stable cTnT elevations would be incorrectly diagnosed with MI. As expected, the absolute cTnT change increased with the cTnT concentration ( Table 3 ), indicating that diagnostic algorithms that use absolute change must take the patient's initial cTnT concentration into account.
There were limitations to this study. The limited number of individuals in the random population did not allow for a reliable determination of the 99th cTnT percentile in the elderly, because a few outliers strongly influenced the calculations. The ER patient population did not include patients with suspected acute coronary syndrome, and the cTnT percentiles may not be representative of this group. The NSTEMI in patients included in the study was diagnosed by use of a cTnT decision threshold of 40 ng/L, which was based on the precision of the previous fourth-generation cTnT assay (24 ) . The distribution of cTnT percentiles in NSTEMI patients is likely to change as the cTnT decision threshold is lowered. However, the percentiles presented here will be updated continuously as more patients are included (27 ). The time intervals and cTnT concentrations were based on retrospective data and must be validated prospectively in acute coronary syndrome patients before they can be introduced in clinical practice.
